Eli Lilly and Company (LLY) Stock: Price, Forecast & Analyst Target
Eli Lilly and Company (LLY) — MoonshotScore 98/100 (Exceptional band), calculated Nov 18, 2026. Price $1351.12 (-2.29%), as of the Nov 19, 2026 trading session; market cap $1.20T. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 245.65× (cash as of Sep 30, 2026) · expected results Feb 3, 2027
Eli Lilly and Company · LLY · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-13: Eli Lilly sells prescription medicines across diabetes, oncology, immunology, neuroscience and pain, with product sales supplying nearly all revenue while collaborations remain ancillary. The case depends on whether rapid medicine-led growth can keep translating into profit and cash while Lilly funds research, production capacity and a debt-heavy balance sheet at a demanding valuation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Eli Lilly and Company (LLY)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
Price relative to book value is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- expected results Feb 3, 2027
- Altman Z 9.45 · Piotroski F 7
Holding back: a rich price
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 90 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional | |
| 98 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1351.12 | |
| Change on the day | -2.29% | |
| 52-week range | $850.51–$1475.25 | |
| Market capitalisation | $1.20T | — |
| Price / earnings (trailing) | 45.83 | |
| Shares traded on the day | 3.07M | |
| Beta (volatility vs the S&P 500) | 0.45 | |
| Dividends per share (last 12 months) | $6.92 | |
| Dividend yield (last 12 months) | 0.49% |
Why Eli Lilly and Company scores 98
Share price, last 12 months +46.1%
$966.64 $1,412
What the price assumes
23.7% a year of free-cash-flow growth for ten years is what a $1.33T market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $19.66B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 2 of those beats. Average first-session move: 8.2% either way.
- +2.7%Feb ’24
- +5.4%Apr ’24
- +15.5%Aug ’24
- -8.2%Oct ’24
- +4.3%Feb ’25
- -8.4%May ’25
- -16.2%Aug ’25
- +6.1%Oct ’25
- +1.7%Feb ’26
- +13.2%Apr ’26
- +6.8%Aug ’26
- +10.0%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +10.0% | +5.9% | |
| Beat | Beat | +6.8% | +9.4% | |
| Beat | Beat | +13.2% | +14.5% | |
| Beat | Beat | +1.7% | +1.2% | |
| Beat | Beat | +6.1% | +15.2% | |
| Beat | Beat | -16.2% | -8.3% | |
| Beat | In line | -8.4% | -16.4% | |
| Beat | — | +4.3% | +3.5% | |
| Miss | Miss | -8.2% | -14.1% | |
| Beat | Beat | +15.5% | +20.6% | |
| Beat | Miss | +5.4% | +5.5% | |
| Beat | Beat | +2.7% | +5.2% |
Beats have usually been rewarded — 9 of 11 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “maintenance doses”, “disciplined approach” — none of them came up in Q2 FY2026.
- Getting louder: “long term” (1 → 5 mentions), “lilly medicine” (2 → 4 mentions), “phase trials” (2 → 4 mentions).
- Gone quiet: “incretin analogs”, “revenue growth” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” rose from 3.2 to 5 per 1,000 words, and confident words such as “record” and “strong” fell from 3.7 to 1.8.
Management chose more careful words than a quarter earlier. Tone shifts like this often show up in the numbers a quarter or two later.
Our track record on this stock
Since the score went from 97 to 98 while the share price moved +8.4% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 74% of 46 rate it a buy; the average target sits +7.0% from the price of $1,351.
- Last 90 days: 18 rating actions, every one a reaffirmation.
- Our signals: Exceptional band; strongest pillar Growth Durability (99), weakest Valuation (34).
Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Based on a strong underlying performance across our portfolio, we now expect full year revenue to be between $91 and $92 billion We saw strength in The U.
Lucas E. Montarce · Statement from
We expect non GAAP earnings per share of $35 to $36 This reflects an increase of $4.07 per share at the midpoint of the range before updates to the Q3 acquired IPR&D charges of $4.57 per share.
Lucas E. Montarce · Statement from
How to read these dates
Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Eli Lilly and Company (LLY): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Eli Lilly and Company (LLY), and what does it report?
Short answer · as of
Lilly is a commercial pharmaceutical manufacturer, not a development-stage biotechnology company waiting on an initial product. Its portfolio spans insulin and other diabetes therapies, cancer medicines, autoimmune treatments, and neurological and pain products; sales rise when those medicines gain use across their approved markets and fall when demand or commercialization weakens.
Research dated 2026-09-13.
Reported revenue overwhelmingly measures product sales. Collaboration and other revenue contributes a much smaller stream, while research spending captures the continuing cost of replenishing and extending the medicine portfolio.
What do the latest results show for Eli Lilly and Company (LLY)?
Research dated 2026-09-13.
The latest results extended a sharp expansion in revenue, gross profit and operating profit. Revenue reached a new high in the reported series, while net income and diluted earnings eased from the immediately preceding period despite stronger operating performance.
Research and selling expenses also rose, so the expanding top line is carrying heavier investment and commercialization spending. Recent reported revenue and adjusted earnings have repeatedly exceeded estimates, and management responded to higher revenue by raising its full-year revenue, margin and earnings outlook.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $24.40B Sep 30, 2026
- Latest quarter · R&D
- $4.25B Sep 30, 2026
- Latest quarter · SG&A
- $3.13B Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $8.61B Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $24.40B | $4.25B | $3.13B | $8.61B |
| Jun 30, 2026 | $22.97B | $3.82B | $3.43B | $12.46B |
| Mar 31, 2026 | $19.80B | $3.51B | $2.93B | $9.78B |
| Dec 31, 2025 | $19.29B | $3.80B | $3.13B | $8.99B |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $24.40B Oct 29, 2026
- Latest report · revenue estimate
- $22.58B Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $24.40B | $22.58B | $7.4800 | $5.7100 |
| Aug 5, 2026 | $22.97B | $20.82B | $8.3800 | $6.4000 |
| Apr 30, 2026 | $19.80B | $17.82B | $8.5500 | $6.9700 |
| Feb 4, 2026 | $19.29B | $17.94B | $7.5400 | $6.9100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $17.60B | $5.58B | $6.21 (diluted) |
| Q4 FY2025 | $19.29B | $6.64B | $7.39 (diluted) |
What are the financial strengths and risks for Eli Lilly and Company (LLY)?
Short answer
Cash and short-term investments were $4.88B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $11.40B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Lilly combines high gross and operating margins with substantial earnings and operating cash generation. Cash flow has strengthened markedly, but capital expenditure remains heavy and variable, reflecting a business that is consuming meaningful cash outside ordinary operations.
Liquidity has improved, yet debt remains far above cash and investments. Strong distress and quality screens provide reassurance about current financial resilience, but they do not remove the exposure created by leverage, elevated capital needs and a valuation that prices sales, earnings and free cash flow richly.
Because product sales dominate revenue, a broad slowdown in medicine demand or commercialization would reach the income statement directly. Lilly would then have less room to absorb research spending and capital investment without leaning further on the balance sheet.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 45.83 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $11.40B Sep 30, 2026
- Previous quarter · operating cash flow
- $10.69B Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $11.40B | −$3.18B |
| Jun 30, 2026 | $10.69B | −$2.93B |
| Mar 31, 2026 | $5.33B | −$2.33B |
| Dec 31, 2025 | $3.22B | −$2.55B |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Eli Lilly and Company (LLY)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027. The number it tests is the $35.45 EPS analysts carry for it.
Research dated 2026-09-13.
Watch whether the next earnings release preserves the recent pattern of revenue and adjusted earnings exceeding expectations. More important than another beat is whether gross profit and operating profit continue rising faster than research and selling costs while net income resumes its advance.
Operating cash flow should also be judged against capital expenditure rather than in isolation. Continued cash accumulation alongside heavy investment would support the current expansion; weaker cash conversion or renewed liquidity erosion would make the debt load more consequential.
Management has tied its raised margin and earnings outlook to higher revenue. Delivery against that linkage would confirm that added medicine sales are converting into operating leverage rather than being absorbed by commercialization, research and acquired development charges.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We will share our 2027 financial guidance on our Q4 call in January.
Lucas E. Montarce ·
Beginning with The US revenue, we expect sustained volume growth in the incretin market and the full year impact of the Medicare GLP-1 bridge access.
Lucas E. Montarce ·
How does Eli Lilly and Company compare with its peers?
Short answer
Eli Lilly and Company's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Lilly differs from an early-stage drug developer because it already markets a broad portfolio across several therapeutic areas and generates substantial profit and cash while continuing to spend heavily on research. The economic engine is commercial medicine volume, not milestone payments: collaboration revenue is comparatively small.
Against other mature pharmaceutical businesses, the notable combination is rapid recent growth, unusually strong margins, heavy reinvestment and a premium market valuation. That mix can reward sustained commercialization success, but it also leaves less room for weakening growth or cash conversion.
| Company | Price | Market value | Score |
|---|---|---|---|
| Eli Lilly and Company (LLY) — this page | $1351.12 | $1.20T | 98 |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $175.41 Nov 19, 2026 | $272B | 85 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $267.14 Nov 19, 2026 | $643B | 83 5-pillar Nov 18, 2026 | |
| $283.54 Nov 19, 2026 | $501B | 83 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $47.82 Nov 19, 2026 | $95.9B | 77 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $132.81 Nov 19, 2026 | $327B | 69 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| $8.20 Nov 19, 2026 | $5.58B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $940.00 – $1650.00
- Consensus target
- $1442.44
- Median target
- $1440.00
- Revenue estimate
- $91.33B
- EPS estimate
- $35.45
Consensus record · Captured .
Measured against a quoted price of $1351.12 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026
- Transactions
- 58
- Identified insiders
- 22
- Purchases
- 0
- Sales
- 4
- Other transactions
- 54
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 87.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 88.9% Prior to period end Sep 30, 2026
- Reporting holders
- 4,755 Period end Sep 30, 2026
- Previous quarter · holders
- 4,817 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Lilly Endowment INC | 90,066,978 |
| Blackrock, INC. | 67,936,153 |
| Vanguard Capital Management LLC | 53,921,209 |
| Pnc Financial Services Group, INC. | 51,295,197 |
| State Street Corp | 36,848,565 |
Tracked investors
Which of the 16 named investors we follow held LLY in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 0.72% | $124.78M | Added +39.6% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.48% | $109.60M | Added +8.8% shares |
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.10% | $4.40M | Trimmed −69.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Eli Lilly and Company (LLY)?
Eli Lilly and Company Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Lilly sell beyond diabetes medicines?
Lilly also markets oncology drugs, autoimmune and inflammatory treatments, and medicines for neurological disorders and pain. These established therapeutic areas make the company broader than a diabetes-only franchise.
How important is collaboration revenue to Lilly?
Collaboration and other revenue is ancillary beside product sales. Lilly's reported growth therefore rests primarily on commercial demand for its medicines rather than partner payments.
Is Lilly increasing research spending while profits grow?
Annual research spending has risen alongside a much faster expansion in revenue and net income. Recent periods also show research expense remaining substantial as Lilly scales its commercial business.
Why is the Lilly Endowment notable in Lilly ownership?
The Lilly Endowment is the largest named institutional holder, ahead of major asset managers in the disclosed holder list. Institutional ownership also increased in the latest reported period, making large holders especially relevant to the shareholder base.
What is the LLY stock price today?
The last price recorded for Eli Lilly and Company (LLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LLY price target?
The analyst consensus price target for Eli Lilly and Company (LLY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 85 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 5 with no recorded source, 5 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold LLY
Funds in our ETF coverage that list LLY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| PBPH ETF | 13.85% | |
| VHT ETF | 12.70% | |
| ProShares - Ultra Health Care (RXL) | 10.22% | |
| IXJ ETF | 10.08% | |
| iShares Evolved U.S. Innovative Healthcare ETF (IEIH) | 7.55% | |
| Simplify Health Care ETF (PINK) | 7.00% | |
| Pathfinder Focused Opportunities ETF (PFOE) | 5.17% | |
| Jensen Quality Growth ETF (JGRW) | 4.86% | |
| PGIM Jennison Focused Growth ETF (PJFG) | 4.42% | |
| SNPG ETF | 4.24% |
